Close

Business & Industry

Abu Dhabi and MSD Partner to Enhance Healthcare Access via New Logistics Hub

The Department of Health – Abu Dhabi (DoH) has announced a strategic collaboration with MSD to evaluate the feasibility of establishing an Abu Dhabi logistics hub. Located within the Health, Endurance, Longevity, and Medicine (HELM) Cluster, this planned facility...

Bayer and Iambic Collaboration Expands AI Drug Discovery Efforts

Bayer has strengthened its pharmaceutical and ophthalmology portfolio through two separate transactions, completing the acquisition of Perfuse Therapeutics while also entering a collaboration agreement with Iambic Therapeutics. The moves provide Bayer with full ownership of Perfuse’s lead asset, PER-001,...

Sanofi Partners with Pangaea for AI-Driven AATD Detection

Pangaea Data (Pangaea), a provider of a guideline-configured AI platform designed to help close care gaps and improve the identification of untreated and under-treated patients with difficult-to-diagnose conditions, has entered into a collaboration agreement with Sanofi. Under the arrangement,...

Lilly and BioArctic Partner on BrainTransporter Technology

Eli Lilly and Company has entered into a research and collaboration agreement with Swedish biopharmaceutical company BioArctic to advance a potential treatment for neurodegenerative diseases. Under the arrangement, the companies will combine BioArctic’s BrainTransporter Technology with an undisclosed Lilly...

AbbVie Acquires Apogee in $10.9 Billion Healthcare Deal

In a significant expansion of its research and development capabilities, a definitive agreement has been reached where AbbVie acquires Apogee Therapeutics for $10.9 billion. This strategic transaction is centered around the addition of zumilokibart, a highly anticipated IL-13 antibody,...

Insilico Medicine Advances ISM8969 Into Phase 1 Trial as Brain-Penetrant NLRP3 Inhibitor for Neuroinflammation

Insilico Medicine has reached a significant clinical milestone with the completion of first-in-human dosing of ISM8969 in a Phase 1 study. Conducted in collaboration with Hygtia Therapeutics, the ISM8969 Phase 1 trial marks the transition of this oral, brain-penetrant...

Moderna Commercial Expansion Accelerates Vaccine Launches

Moderna is strengthening its commercial leadership and operational structure as it prepares for a series of anticipated vaccine launches over the next several years. The company expects potential introductions of its mRNA-based seasonal flu vaccine, combined flu/COVID-19 vaccine, and...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »